Zane Yang, M.D.

  • Chief Medical Officer (CMO), ABM Therapeutics

Dr. Zane Yang, a research physician with more than 20 years’ experience in academic research and the pharma-biotech industry, joined ABM Therapeutics as Chief Medical Officer (CMO) in October 2022.

Before Joining ABM, Dr. Yang was CMO of Denovo Biopharma. During his tenure, he expended and improved company’s clinical research and development capability including two global phase 3 pivotal trials of enzastraurin in patients with newly diagnosed diffuse large B-cell lymphoma or glioblastoma multiforme. Prior to Denovo, Dr. Yang was Senior Vice President and US General Manger of Innovent Biologics. He built the company’s first US R&D center and established multiple clinical trials in the US to develop sintilimab and an anti-CD47 antibody (IBI-188). Before joining Innovent, he was Senior Vice President of Clinical Research and Development for Spectrum Pharmaceuticals, where he led the entire R&D organization with a focus on developing two late-stage investigational drugs, Rolvedon (now it is approved by the US FDA) and poziotinib. In his early career years for the industry, he was Vice President, Oncology Clinical Development of Inovio Pharmaceuticals for DNA based cancer vaccine and therapy development. He also worked for Janssen Biotech / J&J Pharmaceutical Company, Novartis and Merck & Co.

Dr. Yang graduated from Peking University Medical School. Before his industry career, he was associate professor at University of Virginia Medical Center.